目的 探討參一膠囊聯(lián)合FOLFOX4方案治療胃癌的臨床療效。方法 選取2013年2月-2016年5月在江漢大學(xué)附屬醫(yī)院診治的胃癌患者89例，按治療方法不同分為對照組（37例）和治療組（52例）。對照組給予FOLFOX4方案化療：第1天靜脈滴注注射用奧沙利鉑130 mg/m²，滴注時間2 h；第1天靜脈滴注亞葉酸鈣注射液200 mg/m²，滴注時間2 h，爾后先靜脈推注氟尿嘧啶注射液300 mg/m²，然后改為靜脈滴注600 mg/m²，滴注時間22 h；2周為1個化療周期，腫瘤明顯縮小的患者繼續(xù)1個周期化療。治療組患者在對照組基礎(chǔ)上口服參一膠囊，20 mg/次，2次/d，連續(xù)服用28 d。觀察兩組的臨床療效，比較兩組的免疫功能、血清血管內(nèi)皮生長因子（VEGF）水平和不良反應(yīng)情況。結(jié)果 治療后，對照組和治療組的有效率分別為48.6%、71.2%，臨床受益率分別為83.8%、96.2%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，對照組CD³⁺、CD⁴⁺、CD⁸⁺、CD⁴⁺/CD⁸⁺明顯降低，而治療組這些指標明顯升高，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后及術(shù)后3個月，兩組血清VEGF水平均明顯下降，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組血清VEGF水平明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療組白細胞減少、血小板減少、消化系統(tǒng)反應(yīng)、周圍神經(jīng)毒性發(fā)生率明顯少于對照組，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 參一膠囊聯(lián)合FOLFOX4方案治療胃癌具有較好的臨床療效，可降低血清VEGF水平，增強免疫功能，安全性較好，具有一定的臨床推廣應(yīng)用價值。

Objective To study the clinical efficacy of Shenyi Capsules combined with FOLFOX4 regimen in treatment of gastric cancer. Methods Patients (89 cases) with gastric cancer in Affiliated Hospital of Jianghan University from January 2013 to February 2015 were enrolled in this study. According to the difference treatment plan, patients were divided into the control group (37 cases) and treatment group (52 cases). Patients in the control group were given chemotherapy with FOLFOX4 regimen:Patients were iv administered with Oxaliplatin for injection on day 1, 130 mg/m², infusion time of 2 h; Patients were iv administered with Calcium Folinate Injection on day 1, 200 mg/m², infusion time of 2 h. At the same time, patients were iv administered with Fluorouracil Injection on day 1, 300 mg/m², then changed to iv drip, 600 mg/m², infusion time of 22 h, 2 weeks for one chemotherapy cycle. Patients with significantly reduced tumors continued one cycle of chemotherapy. Patients in the treatment group were po administered with Shenyi Capsules on the basis of the control group, 20 mg/time, twice daily, treated for 28 d. After treatment, the clinical efficacies were evaluated, and immune function, serum VEGF levels, and adverse reactions in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 48.6% and 71.2%, clinical benefit rates were 83.8% and 96.2%, respectively, and there was difference between two groups (P<0.05). After treatment, CD³⁺, CD⁴⁺, CD⁸⁺, and CD⁴⁺/CD⁸⁺ in the control group were significantly decreased, but the observational indexes in the treatment group were significantly increased, and there was difference between two groups (P<0.05). After treatment and 3 months after operation, the serum VEGF levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the serum VEGF level in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05). The incidence rates of leukopenia, thrombocytopenia, digestive system reaction, and peripheral neurotoxicity in the treatment group were significantly less than those in the control group, and there was difference between two groups (P<0.05). Conclusion Shenyi Capsules combined with FOLFOX4 regimen has clinical curative effect in the treatment of gastric cancer, and can decrease serum VEGF level, enhance immune function, with good safety, which has a certain clinical application value.